Familial amyloidosis other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) No edit summary |
No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Familial amyloidosis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Fs}},{{F.K}} | ||
==Overview== | ==Overview== | ||
[[Scintigraphy|Total body SAP component scintigraphy]] may be used in the workup and follow-up of patients with [[amyloid]] deposition. This method has been observed to have high [[sensitivity]] (90%) and requires a low [[radioactive]] dose which makes it a safe and effective method. The radiolabeled SAP binds to aa | [[Scintigraphy|Total body SAP component scintigraphy]] may be used in the workup and follow-up of [[Patient|patients]] with [[amyloid]] deposition. This method has been observed to have high [[sensitivity]] (90%) and requires a low [[radioactive]] dose which makes it a safe and effective method. The radiolabeled SAP binds to aa amyloid and localizes its deposition semi-quantitatively. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
===Total Body SAP Scintigraphy=== | ===Total Body SAP Scintigraphy=== | ||
*[[Scintigraphy|Total body SAP component scintigraphy]] may be used in the workup and follow-up of patients with [[amyloid]] deposition.<ref name="Hawkins2002">{{cite journal|last1=Hawkins|first1=Philip N.|title=Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis|journal=Current Opinion in Nephrology and Hypertension|volume=11|issue=6|year=2002|pages=649–655|issn=1062-4821|doi=10.1097/00041552-200211000-00013}}</ref><ref name="Hazenbergvan Rijswijk2006">{{cite journal|last1=Hazenberg|first1=Bouke P.C.|last2=van Rijswijk|first2=Martin H.|last3=Piers|first3=D. Albertus|last4=Lub-de Hooge|first4=Marjolijn N.|last5=Vellenga|first5=Edo|last6=Haagsma|first6=Elizabeth B.|last7=Hawkins|first7=Philip N.|last8=Jager|first8=Pieter L.|title=Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis|journal=The American Journal of Medicine|volume=119|issue=4|year=2006|pages=355.e15–355.e24|issn=00029343|doi=10.1016/j.amjmed.2005.08.043}}</ref> | *[[Scintigraphy|Total body SAP component scintigraphy]] may be used in the workup and follow-up of patients with [[amyloid]] deposition.<ref name="Hawkins2002">{{cite journal|last1=Hawkins|first1=Philip N.|title=Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis|journal=Current Opinion in Nephrology and Hypertension|volume=11|issue=6|year=2002|pages=649–655|issn=1062-4821|doi=10.1097/00041552-200211000-00013}}</ref><ref name="Hazenbergvan Rijswijk2006">{{cite journal|last1=Hazenberg|first1=Bouke P.C.|last2=van Rijswijk|first2=Martin H.|last3=Piers|first3=D. Albertus|last4=Lub-de Hooge|first4=Marjolijn N.|last5=Vellenga|first5=Edo|last6=Haagsma|first6=Elizabeth B.|last7=Hawkins|first7=Philip N.|last8=Jager|first8=Pieter L.|title=Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis|journal=The American Journal of Medicine|volume=119|issue=4|year=2006|pages=355.e15–355.e24|issn=00029343|doi=10.1016/j.amjmed.2005.08.043}}</ref><ref name="PapaLachmann2018">{{cite journal|last1=Papa|first1=Riccardo|last2=Lachmann|first2=Helen J.|title=Secondary, AA, Amyloidosis|journal=Rheumatic Disease Clinics of North America|volume=44|issue=4|year=2018|pages=585–603|issn=0889857X|doi=10.1016/j.rdc.2018.06.004}}</ref> | ||
* This method has been observed to have high [[sensitivity]] (90%) and requires a low [[radioactive]] dose which makes its usage safe and effective. | * This method has been observed to have high [[sensitivity]] (90%) and requires a low [[radioactive]] dose which makes its usage safe and effective. | ||
* However, this imaging modality is unable to identify deposits in hollow, diffuse, or small structures, such as the [[gastrointestinal tract]], [[skin]], and [[nerves]]. | * However, this imaging modality is unable to identify deposits in hollow, diffuse, or small structures, such as the [[gastrointestinal tract]], [[skin]], and [[nerves]]. | ||
* Also, SAP [[scintigraphy]] is unable to detect cardiac and lung involvement due to movement and blood content of these organs. | * Also, SAP [[scintigraphy]] is unable to detect cardiac and lung involvement due to movement and blood content of these organs. | ||
* | * Additionally, uremic [[cardiomyopathy]] is not distinguishable from [[amyloid]] deposition and [[cardiac magnetic resonance]] is relatively [[contraindicated]] in [[patients]] with secondary amyloidosis due to [[Renal failure|advanced renal disease]]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 20:44, 7 February 2020
|
Familial amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Familial amyloidosis other imaging findings On the Web |
|
American Roentgen Ray Society Images of Familial amyloidosis other imaging findings |
|
Risk calculators and risk factors for Familial amyloidosis other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,Farima Kahe M.D. [2]
Overview
Total body SAP component scintigraphy may be used in the workup and follow-up of patients with amyloid deposition. This method has been observed to have high sensitivity (90%) and requires a low radioactive dose which makes it a safe and effective method. The radiolabeled SAP binds to aa amyloid and localizes its deposition semi-quantitatively.
Other Imaging Findings
Total Body SAP Scintigraphy
- Total body SAP component scintigraphy may be used in the workup and follow-up of patients with amyloid deposition.[1][2][3]
- This method has been observed to have high sensitivity (90%) and requires a low radioactive dose which makes its usage safe and effective.
- However, this imaging modality is unable to identify deposits in hollow, diffuse, or small structures, such as the gastrointestinal tract, skin, and nerves.
- Also, SAP scintigraphy is unable to detect cardiac and lung involvement due to movement and blood content of these organs.
- Additionally, uremic cardiomyopathy is not distinguishable from amyloid deposition and cardiac magnetic resonance is relatively contraindicated in patients with secondary amyloidosis due to advanced renal disease.
References
- ↑ Hawkins, Philip N. (2002). "Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis". Current Opinion in Nephrology and Hypertension. 11 (6): 649–655. doi:10.1097/00041552-200211000-00013. ISSN 1062-4821.
- ↑ Hazenberg, Bouke P.C.; van Rijswijk, Martin H.; Piers, D. Albertus; Lub-de Hooge, Marjolijn N.; Vellenga, Edo; Haagsma, Elizabeth B.; Hawkins, Philip N.; Jager, Pieter L. (2006). "Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis". The American Journal of Medicine. 119 (4): 355.e15–355.e24. doi:10.1016/j.amjmed.2005.08.043. ISSN 0002-9343.
- ↑ Papa, Riccardo; Lachmann, Helen J. (2018). "Secondary, AA, Amyloidosis". Rheumatic Disease Clinics of North America. 44 (4): 585–603. doi:10.1016/j.rdc.2018.06.004. ISSN 0889-857X.